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Background
•	Patients

with asplenia are at an increased risk for
infections by encapsulated organisms within the first
2 years post splenectomy. The most common of
these organisms include Streptococcus pneumoniae,
Haemophilus influenzae type b, and Neisseria
meningitidis.
•	Current IDSA and CDC guidelines recommend initial
vaccination with Pneumococcal conjugate vaccine
®
(PCV13, Prevnar ), Haemophilus Influenzae type b
(Hib), Meningococcal (Groups A,C,Y and W-135)
®
Polysaccharide Diphtheria Toxoid Conjugate (Menactra ),
®
and Meningococcal Group B (Bexsero ) or
Meningococcal Group B factor H binding protein
®
(Trumemba ) either 2 weeks prior to elective
splenectomy or within 2 weeks post-emergent
splenectomy.
•	Practice at Lehigh Valley Health Network (LVHN)
Adult patients that are scheduled to undergo
elective splenectomy are encouraged to receive the
recommended vaccines >2 weeks prior to surgery
Adult patients that are admitted for emergent
splenectomy due to trauma are given the vaccines
prior to discharge from the hospital.
All patients that undergo splenectomy are
encouraged to follow up at 8 weeks post-op to
receive PPSV23, MenACWY, and MenB-4C.

© 2019 Lehigh Valley Health Network

Objective
•	Review

vaccination practices in patients postsplenectomy at Lehigh Valley Hospital–Cedar Crest
(LVH–CC) and affiliated outpatient clinics to identify
areas for improvement

Methods:

•	Retrospective

electronic medical record review of
patients admitted to LVH–CC from Aug. 1, 2015
through Aug. 31, 2019 who underwent either
elective or emergent splenectomy
Patients were excluded from analysis if:
		 <
 18 years old
		 N
 o documentation of immunizations in their
electronic medical record
•	Following information was abstracted from patient
charts: age, gender, LVHN primary care physician
(PCP) (yes/no), type of splenectomy surgery
(emergency vs elective), vaccines administered up
to 8 weeks prior to elective splenectomy, vaccines
administered up to 1-year post-splenectomy, and
the location of vaccine administration.

Conclusion

Results
•	95

patients met inclusion criteria
18 patients excluded due to no documentation of
immunizations (15 patients who underwent elective and
3 patients who underwent emergency splenectomy)

Table 2. Rates of appropriate vaccine administration (N=77)
Elective n=59 Emergency n=18
n (%)
All vaccines
Prior to surgery
18 (31)
At least 2 weeks prior to surgery
15 (25)
Prior to discharge
21 (36)
12 (67)
Follow-up vaccines
Within 8 weeks
23 (39)
0 (0)
Within 1 year
25 (42)
0 (0)
At least 1 follow-up vaccine
37 (63)
2 (11)
LVHN PCP
22 (59)
1 (50)
Non-LVHN PCP
15 (41)
1 (50)

Table 1. Baseline characteristics
Elective

Emergency
n (%)

Total Cases (N=77)
Female
LVHN PCP

59 (78)
18 (22)
42 (71)
3 (17)
39 (66)
5 (28)
Average ± Std Dev
57 ± 19.6
64 ± 17.9
6.4 ± 7.7
16.6 ± 13.4

Age (years)
LOS (days)

Graph 1. Percentage of patients receiving all recommended
vaccines

Graph 2. Percentage of patients who received follow-up
vaccines by location
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•	Low

percentage of patients received vaccines prior to elective
splenectomy
Primary care offices do not routinely stock the necessary vaccines to
administer prior to elective surgery
An improvement in pre-surgical planning may increase vaccination rates
•	High percentage of patients who underwent either elective or emergent
splenectomy received at least three of the four recommended vaccines
prior to discharge (83% and 94%, respectively). Greater percentage
received all four vaccines following emergent splenectomy (67%).
No trend exists for what vaccines were missed prior to discharge in
either group
Order set available targeting immunizations post-splenectomy for
emergent procedure
Consider incorporation of recommendations for patients undergoing
elective procedures
•	Similar vaccination completion rates between patients with an LVHN vs
Non-LVHN PCP (35% vs 44%)
•	Rate of vaccine completion within one year of surgery was lower than
expected at 42%.
•	Results of this MUE provide evidence for much needed improvement in
this area of vaccine administration.
The results will be presented to the appropriate departments to help
develop an action plan that will allow us to further align our practices
with the current IDSA and CDC guidelines.
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